NCT01712451View on ClinicalTrials.gov

Dose-ranging Study

PHASE2CompletedINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions

Abdominal Contour Defects

Interventions

DRUG

salmeterol xinafoate, fluticasone propionate

LIPO-102

DRUG

Placebo

Placebo

DRUG

salmeterol xinafoate

Salmeterol

Trial Locations (6)

Unknown

Beverly Hills

San Diego

New York

Raleigh

Nashville

Plano

Sponsors

Lead Sponsor

Neothetics, Inc

All Listed Sponsors

lead

Neothetics, Inc

INDUSTRY